BeyondSpring to Present at the Jefferies Virtual Healthcare Conference on June 3, 2021

Rhea-AI Summary

BeyondSpring is scheduled to present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 9:00 am ET. Interested parties can access the presentation through a live webcast. BeyondSpring focuses on developing innovative cancer therapies, with their lead asset, plinabulin, aimed at preventing chemotherapy-induced neutropenia and enhancing cancer treatment outcomes. A replay of the presentation will be available post-event on their investor relations page.

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 9:00 am ET and will be available for 1x1 meetings.

Details for the event are as follows:

Jefferies Virtual Healthcare Conference
Date:	Thursday, June 3, 2021
Time:	9:00 am ET
Webcast:	https://wsw.com/webcast/jeff174/register.aspx?conf=jeff174&page=bysi&mmid=3325688&refer=meetmax&firstname=&lastname=

A video replay of the presentation will be available on the Events and Presentations investor section of the BeyondSpring website following the conference.

About BeyondSpring
Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring’s first-in-class lead asset plinabulin, is being developed as a “pipeline in a drug.” It is filed for approval in the US and China for the prevention of chemotherapy-induced neutropenia (CIN) and has a fully enrolled pivotal study to test an anti-cancer benefit with an overall survival primary endpoint in non-small cell lung cancer (NSCLC). Additionally, it is being broadly studied in combination with various immuno-oncology regimens that could boost the effects of PD-1 / PD-L1 antibodies. In addition to plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 617-430-7577
arr@lifesciadvisors.com 

Media Contact:
Darren Opland, Ph.D.
LifeSci Communications
+1 646-627-8387
darren@lifescicomms.com

FAQ

When is BeyondSpring's presentation at the Jefferies Virtual Healthcare Conference?

BeyondSpring will present on June 3, 2021, at 9:00 am ET.

How can I access BeyondSpring's presentation at the Jefferies Conference?

You can access it via the live webcast link provided in the press release.

What is the focus of BeyondSpring's development efforts?

BeyondSpring focuses on innovative cancer therapies, particularly through their lead asset, plinabulin.

What is the significance of plinabulin in BeyondSpring's pipeline?

Plinabulin is developed for preventing chemotherapy-induced neutropenia and is involved in various clinical studies.

Where can I find a replay of BeyondSpring's conference presentation?

A video replay will be available on BeyondSpring's investor relations website after the event.